Brokers Set Expectations for Crispr Therapeutics AG's FY2022 Earnings (NASDAQ:CRSP)

The short interest to Crispr Therapeutics AG's float is 11.63%.

At the end of 12/31/2017 reporting period, 47 institutional holders increased their position in CRISPR Therapeutics AG (NASDAQ:CRSP) by some 2,239,704 shares, 19 decreased positions by 1,411,975 and 16 held positions by 7,604,643. Finally, Piper Jaffray Companies initiated coverage on Crispr Therapeutics in a research report on Friday, December 22nd. The stock grabbed 32 new institutional investments totaling 1,383,698 shares while 11 institutional investors sold out their entire positions totaling 160,315 shares. They issued a "hold" rating on the stock. The company has a market cap of $1,690.00 and a price-to-earnings ratio of -115.34. They issued a "hold" rating on the stock. Finally, Oppenheimer reissued a "hold" rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. CRISPR Therapeutics AG disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Legal Officer Dylan-Hyde Tyler has sold 66,000 shares of CRISPR Therapeutics AG (CRSP) in trading session dated January 16, 2018.

COPYRIGHT VIOLATION WARNING: "Crispr Therapeutics (NASDAQ:CRSP) Lifted to "Buy" at SunTrust Banks" was first published by TrueBlueTribune and is owned by of TrueBlueTribune. Zacks Investment Research lowered shares of Crispr Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, January 25th. After $-0.07 actual earnings per share reported by CUI Global, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth. The firm had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. Crispr Therapeutics's revenue was up 54.2% on a year-over-year basis. The rating was initiated by Citigroup with "Neutral" on Tuesday, November 15. BidaskClub raised Crispr Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, January 25th. The company presently has an average rating of "Buy" and a consensus price target of $22.81.

Several analysts have released their opinion on CRISPR Therapeutics AG (NASDAQ:CRSP), with 2 analysts believing it is a strong buy.

In other news, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the firm's stock in a transaction dated Monday, December 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.02). The shares were sold at an average price of $17.76, for a total transaction of $1,156,051.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas Woiwode sold 1,700 shares of Crispr Therapeutics stock in a transaction dated Friday, November 24th. Clear Harbor Asset Management Llc owns 1.18 million shares or 0.86% of their U.S. portfolio. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 2,211,745 shares of company stock valued at $43,953,856.

Institutional investors now hold around $393 million or 38.9% in CRSP stock. Wells Fargo & Company MN's holdings in Crispr Therapeutics were worth $328,000 as of its most recent filing with the Securities & Exchange Commission. Capital Investment Advisory Services LLC acquired a new stake in Crispr Therapeutics in the third quarter valued at approximately $193,000. Ark Investment Management LLC bought a new stake in Crispr Therapeutics during the second quarter worth about $206,000. Moloney Securities Asset Management LLC acquired a new stake in Crispr Therapeutics in the third quarter valued at approximately $235,000. If you are viewing this news story on another site, it was illegally copied and reposted in violation of US and global trademark and copyright legislation.

Crispr Therapeutics AG is a Switzerland-based gene-editing company. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient's cell.

Notícias recomendadas

  • Kings' Fox to replace Lakers' Ball in Rising Stars Challenge

    Kings' Fox to replace Lakers' Ball in Rising Stars Challenge

    The second pick in the draft is averaging 10.2 points, 7.1 rebounds and 7.1 assists in 36 games (all starts). However, in the defense-free zone that is the Rising Stars Challenge, Fox should be entertaining to watch.
    Buffalo woman sees positive changes in Puerto Rico, but challenges remain

    Buffalo woman sees positive changes in Puerto Rico, but challenges remain

    Though this falls short of the petitioned amount, Murphy reassured that his state can shoulder the remained of expenditures. Sunday's explosion increased this number, but authorities managed to restore energy in most of the affected parts.
    U.S.  military leader warns on China

    U.S. military leader warns on China

    Harris's comments also come after Hawaiian residents spent 38 minutes in fear last month after a false missile alert was sent out. A $1 billion radar for Hawaii is in the works and expected to be operational by 2023, which Harris said he is grateful for.
  • MPs warn of

    MPs warn of "erupting" steel pensions scandal

    The BSPS rejected the committee's assertion that its communication to members about their options was "woefully inadequate". The scheme's trustee refuted the conclusion, saying it was "not supported by the evidence".
    China protests Modi's visit to Arunachal Pradesh

    China protests Modi's visit to Arunachal Pradesh

    Modi is expected to visit China in June for a summit of the Chinese and Russian-led Shanghai Cooperation Organization security bloc.
    DCS: Two-year-old girl in foster care taken by her parents

    DCS: Two-year-old girl in foster care taken by her parents

    Kenneth Doziee is 30 years old, 6-foot-2 and 225 pounds with brown eyes and black hair. Tiffany Moore is 30 years old, 5-foot-3 and 250 pounds with brown eyes and red hair.
  • Ryan to House: Pass DACA Bill in March

    Ryan to House: Pass DACA Bill in March

    If he gets it wrong, it will have consequences for him but it will also have consequences for the Republican party. House Republicans argue it's the only bill that would get a majority of their conference and Trump's support.

    Newalta Corporation (TSX:NAL) EBITDA Yield & Shareholder Return Update

    Looking at some alternate time periods, the 12 month price index is 0.44068, the 24 month is 0.50267, and the 36 month is 0.44695. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, price to sales and shareholder yield .
    Boavista vence e ultrapassa Vitória

    Boavista vence e ultrapassa Vitória

    O treinador repetiu que não há pressão adicional para este encontro: "Não lhe chamaria pressão". Sobre o Vitória? "O Guimarães está na luta pela Liga Europa, pelo quinto lugar".
  • Paul School District prepares for possible teacher strike as negotiations continue

    Paul School District prepares for possible teacher strike as negotiations continue

    Teachers are asking for better wages, smaller class sizes and more attention to special education programs. The district seeks to hold new spending to $2 million annually, the Associated Press reported.
    South Korea agrees to pay North Korea's Olympic bill

    South Korea agrees to pay North Korea's Olympic bill

    One former North Korean policeman told CNN that the country's 22 athletes would not even be allowed to go to the bathroom alone. He described them as witnesses "to the ominous nature" of the North Korean regime. "Sports bring people together", Murray said.
    Judge intends to visit giant homeless camp in California

    Judge intends to visit giant homeless camp in California

    The afternoon was spent with both sides negotiating in private until they developed the framework of a deal by the end of the day. Beyond the motel rooms, the county can quickly add 32 beds to its homeless center in Anaheim, which still hasn't fully opened.

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.